240
Participants
Start Date
April 30, 2006
Primary Completion Date
June 30, 2008
Study Completion Date
June 30, 2008
851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
New York
Pittsburgh
Winston-Salem
Charlotte
Augusta
Savannah
Boynton Beach
Tampa
Nashville
Louisville
Detroit
Oklahoma City
Arlington
Houston
Austin
Colorado Springs
San Diego
Colton
Renton
Seattle
Spokane
Moorestown
Québec
Lead Sponsor
Takeda
INDUSTRY